New eczema ointment shows promise in Late-Stage trial
NCT ID NCT07185282
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 study tested MH004 ointment in 375 adolescents and adults with mild to moderate atopic dermatitis (eczema). Participants applied the ointment or a placebo twice daily for 4 weeks, followed by a 44-week safety extension. The main goals were to see if the ointment could clear or nearly clear the skin and reduce eczema severity by at least 75%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MH004 ointment
- What this could lead to
- If successful, this could provide a new topical treatment option for people with mild to moderate atopic dermatitis, helping to clear skin and reduce eczema severity.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The ointment may not work better than a placebo, and long-term safety data are still being analyzed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can ozonated oil soothe eczema in kids?
- Can a Skin-Repairing cream soothe eczema?
- Can a new antibody calm severe eczema?
- Microscopic skin scans may reveal how a new eczema drug reshapes the skin
- Menthol gloves may offer quick itch relief for eczema sufferers
- One pill may tame both itchy skin and stubborn liver disease